Skip to main content
Figure 2 | Journal for ImmunoTherapy of Cancer

Figure 2

From: Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

Figure 2

Naïve mice injected with in vivo treated α-PD-L1 mAb K7M2 cells are non-responsive to α-PD-L1 treatment, suggesting resistance to α-PD-L1 treatment. Naïve Balb/cJ mice were injected with in vivo α-PD-L1 mAb treated metastatic osteosarcoma, with decreased PD-L1 expression, (B) black histogram is PD-L1 expression prior to reimplantation in comparison to mock treated mice in white, and treated with α-PD-L1 mAb or mock (A). No significant difference was seen between survival in treated (n = 10) and untreated (n = 10) mice injected with treated metastatic osteosarcoma (C). PD-L1 expression on metastatic osteosarcoma from mice injected with in vivo α-PD-L1 mAb treated metastatic osteosarcoma compared to control K7M2 injected mice was significantly decreased, p = 0.0026 (D). At time of necropsy, PD-1 + CTLA-4+, and LAG3+ CD8+ expression was evaluated using Flow Jo. PD-1 + CD8+ expression was significantly different in mice injected with in vivo α-PD-L1 mAb treated metastatic osteosarcoma compared to control K7M2 injected mice, p = 0.0017 (E). CTLA-4 + CD8+ expression was significantly different in in vivo α-PD-L1 mAb treated metastatic osteosarcoma injected mice compared to control, p = 0.0231 (F). LAG3 + CD8+ expression was not significantly different between these two groups (G).

Back to article page